What is your impression on #Snibe? Let's explore your answer on our new released video!
关于我们
深圳市新产业生物医学工程股份有限公司成立于1995 年,是专业从事体外诊断产品研发、生产、销售及服务的国家级高新技术企业,注册资本7.8666亿元人民币。公司自成立以来,一直专注于化学发光免疫分析领域的研究,经过十多年的潜心努力,于2008年9月顺利完成中国第一台全自动化学发光仪的注册,并成功推上市场。通过不断的技术创新,公司于2016年将智能化的“模块化生化免疫分析系统”成功推出,进一步丰富了公司产品线。2017年7月,新产业生物通过美国FDA 510(k)审核,成为中国第一家获得美国FDA准入的化学发光厂家。2018年,新产业生物成功发布超高速全自动化学发光免疫分析系统MAGLUMI® X8,开启化学发光超高速的新纪元。2019年7月,新产业生物自主研发的丙型肝炎化学发光产品成功通过欧盟CE List A认证,成为中国第一家丙肝试剂荣获欧盟CE认证的化学发光厂家。2020年12月,新产业生物获中国第一张化学发光领域IVDR CE认证证书,是全球体外诊断领域的先行者之路上新的里程碑。 新产业生物是中国第一家拥有“免疫磁性微球”专利并将其作为化学发光系统关键分离材料的公司,是中国第一家拥有“人工合成的小分子有机化合物-ABEI”专利并用其代替传统的酶作为发光标记物的公司,同时也是中国第一家应用上述专利技术且获得国内注册证并实现批量生产全自动直接化学发光免疫分析仪器及配套试剂的公司。公司的研发成果,填补了国内在体外诊断领域的空白,打破了该领域长期被国外厂家产品垄断和技术封锁的局面,已成为中国化学发光免疫定量分析领域的领导者。 公司主营业务:① 全自动化学发光免疫分析仪器:MAGLUMI® X8、MAGLUMI® X3、MAGLUMI® X6、MAGLUMI® 800、MAGLUMI® 1000、MAGLUMI® 2000、MAGLUMI® 2000 Plus、MAGLUMI® 4000、MAGLUMI® 4000 Plus;配套化学发光试剂:甲状腺功能、性激素、肿瘤标志物、心肌标志物、术前八项、优生优育、糖代谢、骨代谢、肝纤维化、炎症监测、自免抗体等211个检测项目;② 全实验室智能化流水线:新产业-赛默飞SATLARS®-TCA、新产业-日立SMP/SMT、CX8高速生化免疫流水线及配套试剂,SIB超高速生化免疫流水线及配套试剂,HX8超高速生化免疫流水线及配套试剂;③ 全自动生化分析仪器:Biossays®C8、Biossays® BC1200 、Biossays® BC2200;配套生化试剂:血脂、肝功能、肾功能、心肌标志物、糖尿病等检测项目; ④全自动核酸提取纯化仪器:Molecision® MP-96、Molecision® MP-32及配套提取试剂。 公司现有员工2600多人,其中博士、硕士及海外归国人士400多人。公司拥有试剂研发及生产中心、仪器研发及制造中心、营销中心等专业团队支持公司的快速发展。试剂研发及生产中心拥有年产400万盒试剂的产能;仪器研发及制造中心拥有年产3000台全自动化学发光分析仪和1500台模块化生化免疫分析系统的产能;公司国内营销和服务网络已经覆盖到全国所有地区,公司正积极拓展海外市场,目前已与意大利、西班牙、法国、哥伦比亚等150个国家和地区的医院建立了合作关系。 公司一如既往践行我们的使命:以客户为中心,以市场为导向,通过持续不断的产品和技术创新,为人类生命健康事业不断创造价值。
- 所属行业
- 医疗设备制造业
- 规模
- 1,001-5,000 人
- 总部
- Shenzhen,Guangdong
- 类型
- 私人持股
- 创立
- 1995
- 领域
- Diagnostics、Medical Devices、Automated Chemiluminescence Immunoassay (CLIA) System、Integrated system、Reagents和Nano Magnetic Microbead
地点
-
主要
No.23, Jinxiu East Road, Pingshan District, 518122 Shenzhen, P.R. China
CN,Guangdong,Shenzhen,518000
新产业生物员工
-
Raul Vences
Country Manager - Snibe diagnostic
-
Praveen Sharma, PhD,FACBI,FAMS,FADLM
Scientific Consultant Snibe,Former Professor and Head, Biochemistry at All India Institute of Medical Sciences, Jodhpur-342005 ( India)
-
Fabio José Picciarelli
Business Development Manager - SNIBE Brazil
-
Susan Tan
OEM Project Director at Snibe
动态
-
Tomorrow, welcome to join us for an insightful webinar on "Harmonizing Lipid Testing and Reporting in CIinicaI Laboratories: lmplications for CardiovascuIar Risk Management and GIobaI HeaIth"! 🗓 Date: Thursday, Aug. 29th, 2024 🕒 Time: - 20:00 UTC/GMT+8 (Beijing, Singapore) - 08:00 UTC/GMT-4 (Toronto, New York) - 14:00 UTC/GMT+2 (Rome, Paris) Discover the latest innovations and best practices in clinical laboratory medicine to optimize global healthcare. This webinar will provide valuable insights from leading experts in the field. 📲 Mark your calendars and register now via the QR code or click here: https://lnkd.in/g-ijnZHF #CardiovascularHealth #LipidTesting #GlobalHealth #SnibeWebinar #ClinicalLaboratory
-
-
Hepatic B is one of the most common liver infections globally and the leading cause of liver fibrosis, liver cirrhosis, and liver cancer. The detection of HBsAg is essential not only to the diagnosis and classification of both acute and different stages of chronic hepatitis B infection, but also to the monitoring and management of HBV infection. We are delighted to share a research publication to validate MAGLUMI HBsAg assay. The verification data demonstrated that the assay performs very well in sensitivity and reliablility with optimal subgenotype detection efficacy. Here is the link to the original paper: https://lnkd.in/e_xbJKpJ #HepatitisB #LiverHealth #HBV #InfectionDetection
-
Two days left! Welcome to join us for an insightful webinar on "Harmonizing Lipid Testing and Reporting in CIinicaI Laboratories: lmplications for CardiovascuIar Risk Management and GIobaI HeaIth"! 🗓 Date: Thursday, Aug. 29th, 2024 🕒 Time: - 20:00 UTC/GMT+8 (Beijing, Singapore) - 08:00 UTC/GMT-4 (Toronto, New York) - 14:00 UTC/GMT+2 (Rome, Paris) Discover the latest innovations and best practices in clinical laboratory medicine to optimize global healthcare. This webinar will provide valuable insights from leading experts in the field. 📲 Mark your calendars and register now via the QR code or click here: https://lnkd.in/g-ijnZHF #CardiovascularHealth #LipidTesting #GlobalHealth #SnibeWebinar #ClinicalLaboratory
-
-
🎉Celebrating 29 Years of Innovation!🎉 Snibe is proud to mark 29 years of advancing healthcare through cutting-edge diagnostics. From our beginnings to becoming a global leader, our mission has been clear: making quality healthcare accessible and affordable. Thank you to our team, partners, and customers for being part of this journey. Here's to many more years of innovation! 🚀 #Snibe #Anniversary #Healthcare #Diagnostics
-
-
WHO published "Strengthening Diagnostic Capacity" and emphasized the importance of diagnostics in health care. Focused on chemiluminescence immunoassay for 29 years, Snibe has achieved more than 30,000 fully automated CLIA analyzers installed in laboratories across 156 countries and regions and strives to provide quality, comprehensive and integrated primary health care and health services everywhere and for everyone. We will firmly implement the corporate mission of being "customer-centered, market-oriented, through continuous product and technology innovation, continue to create value for global healthcare" and persistently contribute intellect and vigor to the noble mission of human health. #Snibe #SnibeDiagnostic #Diagnostic #WHO #HealthCareForAll #CorporateMission
-
-
One week later! Welcome to join us for an insightful webinar on "Harmonizing Lipid Testing and Reporting in CIinicaI Laboratories: lmplications for CardiovascuIar Risk Management and GIobaI HeaIth"! 📅 Date: Thursday, Aug. 29th, 2024 🕒 Time: - 20:00 UTC/GMT+8 (Beijing, Singapore) - 08:00 UTC/GMT-4 (Toronto, New York) - 14:00 UTC/GMT+2 (Rome, Paris) Discover the latest innovations and best practices in clinical laboratory medicine to optimize global healthcare. This webinar will provide valuable insights from leading experts in the field. 📲 Mark your calendars and register now via the QR code or click here: https://lnkd.in/g-ijnZHF #CardiovascularHealth #LipidTesting #GlobalHealth #SnibeWebinar #ClinicalLaboratory
-
-
Type 1 diabetes is an autoimmune condition where the body’s immune system mistakenly targets and destroys the insulin-producing cells in the pancreas. Without insulin, the body can’t regulate blood sugar properly. One of the early signs of this process is the presence of specific autoantibodies—like ICA, GADA, IA-2A, and IAA—which signal that the immune system is attacking the pancreas. Understanding the role of autoantibodies in Type 1 diabetes can empower patients and healthcare providers to take proactive steps. Snibe offers a full range of immunoassay tests with high sensitivity to help effectively detect these markers, providing crucial support for early diagnosis and better management of the disease. The earlier you know, the better you can manage it. #Type1Diabetes #Autoantibodies #EarlyDiagnosis #HealthcareInnovation
-
-
Accelerate your lab with the Biolumi CX8—the all-in-one solution for immunoassay and biochemistry! ✨ Ultra-high throughput in a compact design ✨ Cutting-edge technologies for superior performance ✨ Customizable TLA expandability to meet diverse lab needs Discover more: https://lnkd.in/gs2a6F-c #BiolumiCX8 #Immunoassay #Biochemistry #IntegratedSystem
-
-
Exciting Research Alert! As the global health community continues to respond to the monkeypox outbreak, accurate and reliable diagnostic testing is crucial for identifying and managing cases. Shenzhen Center for Disease Control and Prevention and Snibe R&D team have conducted a comprehensive evaluation of three diagnostic assays for the detection of human monkeypox. Molecision (Snibe) Monkeypox Virus qPCR Assay and MAGLUMI (Snibe) Monkeypox Virus Ag (CLIA) Assay demonstrated good accuracy and high sensitivity. The latest literature provides valuable insights into the performance and characteristics of these assays. We invite you to download and share our poster and paper to learn more about the findings and their implications for public health practice. Paper: https://lnkd.in/gmpEjW3w #Monkeypox #DiagnosticResearch #PublicHealth #Snibe